vs
AGIOS PHARMACEUTICALS, INC.（AGIO）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
AGIOS PHARMACEUTICALS, INC.的季度营收约是STANDARD BIOTOOLS INC.的1.0倍（$20.0M vs $19.6M），STANDARD BIOTOOLS INC.净利率更高（-177.4% vs -541.1%，领先363.7%），AGIOS PHARMACEUTICALS, INC.同比增速更快（86.1% vs -11.5%），STANDARD BIOTOOLS INC.自由现金流更多（$-23.1M vs $-97.3M），过去两年AGIOS PHARMACEUTICALS, INC.的营收复合增速更高（56.1% vs -12.2%）
Agios Pharmaceuticals是一家美国上市制药企业，创立于2008年，专注于开发针对基因定义疾病的创新疗法，近期核心方向为溶血性贫血治疗药物，总部位于马萨诸塞州剑桥市，2013年7月完成首次公开募股。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
AGIO vs LAB — 直观对比
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $20.0M | $19.6M |
| 净利润 | $-108.0M | $-34.7M |
| 毛利率 | 90.6% | 48.5% |
| 营业利润率 | -608.9% | -168.5% |
| 净利率 | -541.1% | -177.4% |
| 营收同比 | 86.1% | -11.5% |
| 净利润同比 | -11.9% | -28.8% |
| 每股收益（稀释后） | $-1.86 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $20.0M | — | ||
| Q3 25 | $12.9M | $19.6M | ||
| Q2 25 | $12.5M | $21.8M | ||
| Q1 25 | $8.7M | $40.8M | ||
| Q4 24 | $10.7M | — | ||
| Q3 24 | $9.0M | $22.1M | ||
| Q2 24 | $8.6M | $22.5M | ||
| Q1 24 | $8.2M | $45.5M |
| Q4 25 | $-108.0M | — | ||
| Q3 25 | $-103.4M | $-34.7M | ||
| Q2 25 | $-112.0M | $-33.5M | ||
| Q1 25 | $-89.3M | $-26.0M | ||
| Q4 24 | $-96.5M | — | ||
| Q3 24 | $947.9M | $-26.9M | ||
| Q2 24 | $-96.1M | $-45.7M | ||
| Q1 24 | $-81.5M | $-32.2M |
| Q4 25 | 90.6% | — | ||
| Q3 25 | 87.0% | 48.5% | ||
| Q2 25 | 86.3% | 48.8% | ||
| Q1 25 | 87.6% | 48.4% | ||
| Q4 24 | 88.3% | — | ||
| Q3 24 | 91.3% | 54.9% | ||
| Q2 24 | 82.6% | 46.1% | ||
| Q1 24 | 92.3% | 53.1% |
| Q4 25 | -608.9% | — | ||
| Q3 25 | -907.4% | -168.5% | ||
| Q2 25 | -1020.1% | -118.1% | ||
| Q1 25 | -1222.0% | -80.8% | ||
| Q4 24 | -1165.3% | — | ||
| Q3 24 | -1146.9% | -120.9% | ||
| Q2 24 | -1228.3% | -134.5% | ||
| Q1 24 | -1124.3% | -132.2% |
| Q4 25 | -541.1% | — | ||
| Q3 25 | -803.1% | -177.4% | ||
| Q2 25 | -899.4% | -153.7% | ||
| Q1 25 | -1023.3% | -63.8% | ||
| Q4 24 | -899.6% | — | ||
| Q3 24 | 10574.7% | -122.0% | ||
| Q2 24 | -1115.7% | -203.3% | ||
| Q1 24 | -995.8% | -70.6% |
| Q4 25 | $-1.86 | — | ||
| Q3 25 | $-1.78 | $-0.09 | ||
| Q2 25 | $-1.93 | $-0.09 | ||
| Q1 25 | $-1.55 | $-0.07 | ||
| Q4 24 | $-1.44 | — | ||
| Q3 24 | $16.22 | $-0.07 | ||
| Q2 24 | $-1.69 | $-0.12 | ||
| Q1 24 | $-1.45 | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $89.1M | $129.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.2B | $399.7M |
| 总资产 | $1.3B | $539.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $89.1M | — | ||
| Q3 25 | $92.7M | $129.4M | ||
| Q2 25 | $80.9M | $158.6M | ||
| Q1 25 | $79.0M | $150.9M | ||
| Q4 24 | $76.2M | — | ||
| Q3 24 | $253.7M | $210.6M | ||
| Q2 24 | $84.5M | $269.8M | ||
| Q1 24 | $118.8M | $287.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $55.2M | ||
| Q2 24 | — | $55.1M | ||
| Q1 24 | — | $55.0M |
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.3B | $399.7M | ||
| Q2 25 | $1.4B | $424.5M | ||
| Q1 25 | $1.5B | $454.6M | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.6B | $489.3M | ||
| Q2 24 | $660.5M | $510.3M | ||
| Q1 24 | $743.9M | $577.3M |
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.4B | $539.6M | ||
| Q2 25 | $1.5B | $557.0M | ||
| Q1 25 | $1.6B | $579.6M | ||
| Q4 24 | $1.7B | — | ||
| Q3 24 | $1.8B | $681.5M | ||
| Q2 24 | $773.1M | $708.7M | ||
| Q1 24 | $849.7M | $777.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.11× | ||
| Q1 24 | — | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-96.2M | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | $-97.3M | $-23.1M |
| 自由现金流率自由现金流/营收 | -487.5% | -118.1% |
| 资本支出强度资本支出/营收 | 5.6% | 4.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-377.3M | $-111.1M |
8季度趋势，按日历期对齐
| Q4 25 | $-96.2M | — | ||
| Q3 25 | $-88.2M | $-22.2M | ||
| Q2 25 | $-77.1M | $-20.7M | ||
| Q1 25 | $-111.5M | $-30.3M | ||
| Q4 24 | $-133.2M | — | ||
| Q3 24 | $-84.2M | $-27.9M | ||
| Q2 24 | $-72.6M | $-39.0M | ||
| Q1 24 | $-99.9M | $-62.5M |
| Q4 25 | $-97.3M | — | ||
| Q3 25 | $-89.7M | $-23.1M | ||
| Q2 25 | $-78.0M | $-22.6M | ||
| Q1 25 | $-112.3M | $-35.3M | ||
| Q4 24 | $-134.1M | — | ||
| Q3 24 | $-84.6M | $-30.1M | ||
| Q2 24 | $-72.7M | $-41.0M | ||
| Q1 24 | $-100.0M | $-63.3M |
| Q4 25 | -487.5% | — | ||
| Q3 25 | -696.5% | -118.1% | ||
| Q2 25 | -626.2% | -103.6% | ||
| Q1 25 | -1286.4% | -86.6% | ||
| Q4 24 | -1250.1% | — | ||
| Q3 24 | -944.2% | -136.4% | ||
| Q2 24 | -844.4% | -182.2% | ||
| Q1 24 | -1221.2% | -138.9% |
| Q4 25 | 5.6% | — | ||
| Q3 25 | 12.1% | 4.5% | ||
| Q2 25 | 7.0% | 8.7% | ||
| Q1 25 | 8.8% | 12.4% | ||
| Q4 24 | 9.0% | — | ||
| Q3 24 | 4.7% | 10.2% | ||
| Q2 24 | 1.8% | 8.6% | ||
| Q1 24 | 1.7% | 1.7% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.09× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AGIO
暂无分部数据
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
